These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 34966024)

  • 1. Limited Longitudinal Change in Self-reported Spatial Navigation Ability in Preclinical Alzheimer Disease.
    Levine TF; Roe CM; Babulal GM; Fagan AM; Head D
    Alzheimer Dis Assoc Disord; 2022 Jan-Mar 01; 36(1):15-21. PubMed ID: 34966024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alzheimer disease biomarkers are associated with decline in subjective memory, attention, and spatial navigation ability in clinically normal adults.
    Levine TF; Dessenberger SJ; Allison SL; Head D;
    J Int Neuropsychol Soc; 2024 May; 30(4):313-327. PubMed ID: 38014546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.
    Sutphen CL; Jasielec MS; Shah AR; Macy EM; Xiong C; Vlassenko AG; Benzinger TL; Stoops EE; Vanderstichele HM; Brix B; Darby HD; Vandijck ML; Ladenson JH; Morris JC; Holtzman DM; Fagan AM
    JAMA Neurol; 2015 Sep; 72(9):1029-42. PubMed ID: 26147946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical utility of self- and informant-reported memory, attention, and spatial navigation in detecting biomarkers associated with Alzheimer disease in clinically normal adults.
    Levine TF; Allison SL; Dessenberger SJ; Head D;
    J Int Neuropsychol Soc; 2024 Mar; 30(3):232-243. PubMed ID: 37642015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alzheimer Disease Biomarkers and Driving in Clinically Normal Older Adults: Role of Spatial Navigation Abilities.
    Allison S; Babulal GM; Stout SH; Barco PP; Carr DB; Fagan AM; Morris JC; Roe CM; Head D
    Alzheimer Dis Assoc Disord; 2018; 32(2):101-106. PubMed ID: 29578861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults.
    Dumurgier J; Hanseeuw BJ; Hatling FB; Judge KA; Schultz AP; Chhatwal JP; Blacker D; Sperling RA; Johnson KA; Hyman BT; Gómez-Isla T
    J Alzheimers Dis; 2017; 60(4):1451-1459. PubMed ID: 29036824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
    Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
    Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
    J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.
    Tarawneh R; Head D; Allison S; Buckles V; Fagan AM; Ladenson JH; Morris JC; Holtzman DM
    JAMA Neurol; 2015 Jun; 72(6):656-65. PubMed ID: 25867677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of Racial Disparities in Biomarkers for Alzheimer Disease.
    Morris JC; Schindler SE; McCue LM; Moulder KL; Benzinger TLS; Cruchaga C; Fagan AM; Grant E; Gordon BA; Holtzman DM; Xiong C
    JAMA Neurol; 2019 Mar; 76(3):264-273. PubMed ID: 30615028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physical Exercise and Longitudinal Trajectories in Alzheimer Disease Biomarkers and Cognitive Functioning.
    Stojanovic M; Jin Y; Fagan AM; Benzinger TL; Hassenstab J; Cruchaga C; Morris JC; Head D
    Alzheimer Dis Assoc Disord; 2020; 34(3):212-219. PubMed ID: 32520736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-Correlated Cerebrospinal Fluid Biomarker Trajectories in Preclinical Alzheimer's Disease.
    Gomar JJ; Conejero-Goldberg C; Davies P; Goldberg TE;
    J Alzheimers Dis; 2016; 51(4):1085-97. PubMed ID: 26967213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mood Changes in Cognitively Normal Older Adults are Linked to Alzheimer Disease Biomarker Levels.
    Babulal GM; Ghoshal N; Head D; Vernon EK; Holtzman DM; Benzinger TLS; Fagan AM; Morris JC; Roe CM
    Am J Geriatr Psychiatry; 2016 Nov; 24(11):1095-1104. PubMed ID: 27426238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sex differences in CSF biomarkers vary by Alzheimer disease stage and
    Babapour Mofrad R; Tijms BM; Scheltens P; Barkhof F; van der Flier WM; Sikkes SAM; Teunissen CE
    Neurology; 2020 Oct; 95(17):e2378-e2388. PubMed ID: 32788242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developing a Spatial Navigation Screening Tool Sensitive to the Preclinical Alzheimer Disease Continuum.
    Allison SL; Rodebaugh TL; Johnston C; Fagan AM; Morris JC; Head D
    Arch Clin Neuropsychol; 2019 Oct; 34(7):1138-1155. PubMed ID: 31197326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
    JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypothetical Preclinical Alzheimer Disease Groups and Longitudinal Cognitive Change.
    Soldan A; Pettigrew C; Cai Q; Wang MC; Moghekar AR; O'Brien RJ; Selnes OA; Albert MS;
    JAMA Neurol; 2016 Jun; 73(6):698-705. PubMed ID: 27064267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time Trends of Cerebrospinal Fluid Biomarkers of Neurodegeneration in Idiopathic Normal Pressure Hydrocephalus.
    Lukkarinen H; Tesseur I; Pemberton D; Van Der Ark P; Timmers M; Slemmon R; Janssens L; Streffer J; Van Nueten L; Bottelbergs A; Rauramaa T; Koivisto AM; Herukka SK; Korhonen VE; Junkkari A; Hiltunen M; Engelborghs S; Blennow K; Zetterberg H; Kolb HC; Leinonen V
    J Alzheimers Dis; 2021; 80(4):1629-1642. PubMed ID: 33720890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.